Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

  • Technology appraisal guidance
  • TA316
  • Published: 

Review decision – December 2017

Decision to incorporate into an ongoing clinical guideline update

The Institute was proposing that the guidance should be incorporated into an ongoing clinical guideline update of CG175 (prostate cancer: diagnosis and management).

 After consideration of all of the comments received during the review consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, the guidance will be incorporated into an ongoing clinical guideline update. The technology appraisals will remain extant alongside the guideline.

Review decision paper

This page was last updated: